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Abstract
Introduction: Cartilage oligomeric matrix protein (COMP) is a major non-collagenous component of cartilage.
Earlier, we developed a new mouse model for rheumatoid arthritis using COMP. This study was undertaken to
investigate the epitope specificity and immunopathogenicity of COMP-specific monoclonal antibodies (mAbs).
Methods: B cell immunodominant regions on the COMP molecule were measured with a novel enzyme-linked
immunosorbent assay using mammalian expressed full-length mouse COMP as well as a panel of recombinant
mouse COMP fragments. 18 mAbs specific to COMP were generated and the pathogenicity of mAbs was
investigated by passive transfer experiments.
Results: B cell immunodominant epitopes were localized within 4 antigenic domains of the COMP but with
preferential response to the epidermal growth factor (EGF)-like domain. Some of our anti-COMP mAbs showed
interactions with the native form of COMP, which is present in cartilage and synovium. Passive transfer of COMP-
specific mAbs enhanced arthritis when co-administrated with a sub-arthritogenic dose of a mAb specific to
collagen type II. Interestingly, we found that a combination of 5 COMP mAbs was capable of inducing arthritis in
naive mice.
Conclusions: We have identified the specificities of mAbs to COMP and their contribution to the development of
arthritis. These findings will further improve our understanding of the autoantibody mediated immunopathologies
occurring widely in rheumatoid arthritis (RA), as well as in other autoimmune disorders.
Introduction
Rheumatoid arthritis (RA) is believed to be an autoim-
mune disease involving an antibody response to citrulli-
nated proteins (ACPA) [1,2] and Ig-Fc (rheumatoid factor,
RF) [3]. In many patients with established disease, an anti-
body response to joint cartilage may also appear [4]. Both
antibodies to native triple helical collagen type II (CII) and
ACPA recognizing citrullinated CII have been shown to
induce arthritis in mice [5-8]. Clinical trials of B cell deple-
tion treatment using rituximab, an anti-CD20 monoclonal
antibody, which targets and deletes CD20-expressing B
cells, achieved promising clinical outcomes in RA patients
[9,10]. These findings in both patients and animal models
highlight the role of antibodies in RA.
Cartilage oligomeric matrix protein (COMP) is a major
glycoprotein in the extracellular matrix (ECM) of cartilage
and synovium [11]. Its biological importance in cartilage
was identified in the assembly of the ECM, where COMP
interacts with fibrillar collagen types I and II and the
FACIT collagen type IX [12,13]. Mutations in the COMP
gene have been linked to two human skeletal dysplasias,
pseudoachondroplasia (PSACH) and multiple epiphyseal
dysplasia (MED) [14,15].
We have developed a new mouse model for rheumatoid
arthritis using COMP, where immunization with rat
COMP is associated with development of autoimmune
arthritis by cross-reactive immune response to autologous
mouse COMP [16,17]. The pathology of arthritis induced
by COMP immunization shows similarities with human
RA having synovial hyperplasia, increased synovial volume,
cellular infiltrates, and the unique feature of a chronic
relapsing disease phase with a female preponderance. As
in RA, the development of arthritis induced by COMP is
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associated with certain major histocompatibility complex
(MHC) haplotypes, indicating that the COMP-induced
arthritis (COMPIA) model is dependent on T cell recogni-
tion of related peptides presented by appropriate MHC
molecules. However, T-cell reactivity alone could not
explain the disease immunopathology in COMPIA.
COMP-immunized mice have been shown to develop a
strong and specific IgG response to COMP, and analysis
of blood cell populations in arthritic mice showed an
increase in B cells, CD4+ T cells but not cytotoxic CD8+
T cells. Furthermore, arthritis can be transferred from
arthritic mice to healthy recipients with affinity purified
COMP-specific polyclonal antibodies [17]. It has been ear-
lier reported that anti-COMP antibodies exist in RA syno-
vium and serum, which possibly reflects joint local B cell
immune responses toward this cartilage- and tendon-
restricted antigen [18].
COMP is the fifth member of the thrombospondin
(TSP) protein family, which includes TSP-1, TSP-2, TSP-
3, TSP-4 and COMP/TSP-5. COMP is a homopentamer
and each of its subunits consists of an N-terminal coiled-
coil oligomerization domain, four EGF-like repeats, eight
calcium-binding type 3 (TSP3) repeats and a C-terminal
globular domain (Figure 1). To fully understand the
immunological events in COMP induced arthritis, it is
necessary to identify the immunodominant region of B
cell reactivity and demonstrate the contribution of antibo-
dies in arthritis pathology. To identify the domains of the
COMP molecule that are recognized by antibodies, we
produced mammalian-expressed full-length mouse COMP
and a panel of overlapping recombinant mouse COMP
fragments. Furthermore, we developed 21 monoclonal
antibodies directed to rat COMP, 18 mAbs reactive with
rat COMP cross-reacted with mouse COMP. Here, we
demonstrate the specificity of polyclonal antibodies and
monoclonal antibodies for different domains of the
COMP molecule. COMP-specific mAbs interact with
native COMP in cartilage and synovium, as evidenced by
the binding of biotinylated mAbs in vivo. Passive transfer
of selected anti-COMP mAbs- enhanced arthritis when
co-administered with a sub-arthritogenic dose of a mAb
that specifically recognizes the J1 epitope of the CII mole-
cule [19]. A combination of five selected COMP mAbs,
without anti-CII mAb, was also effective to induce arthritis
in naïve mice, although with low severity of arthritis.
Materials and methods
Animals
COMP-deficient 129/Sv mice [20] were backcrossed for 10
generations to B10.Q mice to introduce the Aq allele in the
MHC locus. B10.Q mice with a mutated Ncf1 (Ncf1m1J
denoted as Ncf1*) have been described previously [21]. To
obtain mice with COMP-deficiency and Ncf1 mutation
(COMP-/-Ncf1*/*), COMP-deficient B10.Q mice were
intercrossed with Ncf1mutant mice to get COMP-deficient
and Ncf1 mutated heterozygous mice. These heterozygous
mice were intercrossed and the offspring were investigated
for COMP deficiency and Ncf1 mutation by PCR and DNA
sequence respectively [21,22]. For passive transfer experi-
ments (BALB/c × B10.Q) F1 male mice (known as QB)
were used; these showed higher sensitivity to antibody-
induced arthritis [7]. All the mice were kept and bred in a
climate-controlled environment with a 12-h light/dark
cycle. Mice were housed in polystyrene cages containing
wood shavings and fed standard rodent chow and water ad
libitum in the animal house of Medical Inflammation
Research, Sweden. All the experiments were performed
using age-matched mice between 8 and 10 weeks and
blinded to the investigator. Malmö/Lund and Stockholm
ethical committees approved all the experiments.
Production of recombinant COMP proteins
The corrected cDNA for mouse COMP [22] served as the
template for PCR amplification of the following recombi-
nant COMP fragments (Figure 1). In addition to full-
length his-tagged mouse COMP (pCOMP, nucleotide 82-
2289), the fragments produced were; (1) mCOMP, mono-
meric COMP, that is, only lacking the coiled-coil repeats,
nucleotide 238-2289; (2) EGF1-TIII8, EGF-like repeats
and TSP3 repeats, nucleotide 238-1569; (3) TIII1-CG,
TSP3 repeats and C-terminal globular domain, nucleotide
820-2289; (4) EGF1-4, EGF-like repeats, nucleotide 238-
819; (5) TIII1-8, TSP3 repeats, nucleotide 820-1569, and
(6) CG, C-terminal globular domain, nucleotide 1570-
2289 [NM_016685.2, GenBank]. The mouse COMP
recombinant fragment cDNAs were amplified using 5’-
phosphorylated upstream primers in combination with
downstream primers adding a stop codon followed by an
Nhe I site. The PCR products were digested with Nhe I
and inserted into the Pvu II and Nhe I sites of the expres-
sion vector pCEP4-TAGZyme. This plasmid was con-





Kpn I and HinDIII sites of plasmid pCEP4, yielding an
expression vector with a BM40 signal peptide followed by
a hexahistidine tag compatible with the TAGZyme
removal system (Qiagen, Copenhagen, Denmark). All the
PCR-generated fragments and their cloning sites were
confirmed by nucleotide sequencing.
The resulting recombinant COMP plasmids were
transfected into 293-c18 cells (ATCC CRL-10852) using
the FuGene6 reagent (Roche, Basel, Switzerland ) and
transfected cells were selected with hygromycin and
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grown to confluence in Dulbecco’s modified Eagle’s
medium with 10% fetal calf serum (Gibco, Life Technol-
ogies Inc, Camarillo, CA, USA). Secretion of recombi-
nant proteins into the medium was confirmed by SDS-
PAGE of samples from transfected and non-transfected
cells. Serum-free culture medium was harvested, and
his-tagged recombinant mouse COMP proteins were
purified using Ni2+-metal chelating and MonoQ ion
exchange chromatography. Purity and size of all the pro-
teins were assessed by SDS-PAGE and colloidal Coo-
massie Brilliant Blue G250 staining with or without
prior reduction of disulfide bonds.
Figure 1 Relative level and kinetics of the antibody response to each truncated cartilage oligomeric matrix protein (COMP) fragment.
(A) Graphical representation of the domain composition of the recombinant mouse COMP proteins used in this study. pCOMP: pentameric
COMP; mCOMP: monomeric COMP; EGF: epidermal growth factor; TIII: thrombospondin type 3; CG: C-terminal globular domain. (B) Medium was
collected from each transfected cell line and purified using Ni-NTA affinity resin followed by a concentration step using ion-exchange
chromatography as described in Materials and methods, and 10 μl of the purified proteins were subjected to 4 to 10% gradient SDS-PAGE under
reducing conditions. (C) Relative level of antibody response to different recombinant COMP fragments. Full length COMP (pCOMP) and COMP
fragments (10 μg/ml in 100 μl) were tested by ELISA for COMP autoantibody response. Serum samples from COMP+/+Ncf1*/*mice were taken at
day 50 after immunization with rat COMP and diluted 1:1000 for the assay. Background levels were determined for each test using antigen,
coated, but without primary antibodies in the wells. Results are expressed as absorbance reading at 405 nm and represent the mean and SEM of
13 mice. The lower binding to the TIII1-CG fragment compared to pCOMP, mCOMP or EGF1-TIII8 was confirmed to be statistically significant (P ≤
0.05). (D) Kinetics of antibody response to rat COMP, full length mouse COMP (pCOMP) and mouse COMP fragments. Serum samples from
COMP+/+Ncf1*/* mice were taken at days 15, 30, 50 and 85 after immunization with rat COMP and were subjected to ELISA. Sera were diluted
1:1000 for the assays. Data represent the mean values from 13 mice.
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Rat COMP purification
Purification of COMP from the Swarm rat chondrosar-
coma was performed as previously described [17]. Briefly,
50 g rat chondrosarcoma was homogenized and centri-
fuged, the pellet was extracted in 150 mM NaCl, 50 mM
Tris, 10 mM EDTA, pH 7.4, supernatants were harvested,
and COMP was purified using DEAE-Sepharose fast-flow
media column (GE Healthcare, Uppsala, Sweden), COMP-
containing fractions were evaluated by SDS-PAGE. Pooled
fractions were then exchanged to 150 mM NaCl, 10 mM
Tris, and 2 mM EDTA, pH 7.4 buffer. Pooled fractions
were concentrated and negatively purified using HiTrap
heparin-Sepharose column, HiTrap Q Sepharose column,
heparin column (GE Healthcare, Uppsala, Sweden) and Q
column. The purity and size of COMP fractions were
assessed by SDS-PAGE under reducing and non-reducing
conditions.
Synthetic peptides
Sequence alignment identified 15 amino acid differences
between the mature peptide sequences of rat and mouse
COMP. The following peptides, corresponding to the
rat COMP sequence and containing the amino acids differ-
ing from mouse COMP (underlined), were synthesized
using methods previously described in detail [8]. P1:
DVRELLRHRVKEITFLK (in coiled-coil repeats); P2:
PGLSVRPVALCAPGSCF (in EGF1); P3: SCFPGVVCTE-
TATGARC (in EGF1); P4: GVGLTFAKTNKQVCTDI (in
EGF2); P5: QPGFVGDQRSGCQRRGQ (in EGF3); P6:
PSPCHEKADCILERDGSRS (in EGF4); P7: GQEDVDR-
DRIGDACDPD (in TIII2); P8: NPDQRNSDKDKWGDAC
D (in TIII3); P9: DACDNCRSQKNDDQKDT (in TIII4);
P10: NDDQKDTDRDGQG DACDDDI (in TIII4); P11:
DTIPEDYERHRLRRA (C-terminal peptide). Peptide identi-
ties were confirmed by mass spectrometry and fast protein
liquid chromatography was used to maintain purity at >
98% (Hermann GbR Synthetische Biomoleküle, Freiburg,
Germany).
Generation of COMP-specific B cell hybridomas
Hybridomas producing anti-COMP mAbs were generated
as described earlier [23]. Briefly, COMP-/-Ncf1*/* and
COMP+/+Ncf1*/* mice were immunized at the base of the
tail with 100 μg of rat COMP emulsified in complete
Freund’s adjuvant (CFA; Difco, Detroit, MI, USA), fol-
lowed by an i.p. booster with 50 μg of rat COMP in PBS.
Three to five days after the booster dose, spleen or ingu-
inal lymph cells were fused with SP2/0 or NSO-bcl2 mye-
loma cell lines. Two weeks after the fusion, all the primary
plates were screened for antibody production by ELISA
using rat COMP. Cells from positive wells were sub-
cloned 5 times by limiting dilution and expanded for
further use. Monoclonal antibodies were purified from the
supernatants by affinity chromatography using protein G
column (GammaBind plus Sepharose; GE Healthcare,
Uppsala, Sweden) and bound IgG was eluted in 0.1 M gly-
cine (pH 2.8) and neutralized with one-sixth volume of
1 M Tris-HCl (pH 8.5). The eluted fractions were dialyzed
against PBS buffer extensively. Monoclonal antibodies
were quantified by measuring absorbance at 280 nm and
the purity of the antibodies was assessed by SDS-PAGE.
The endotoxin content in all mAbs preparations was
found to be below detection limit (less than 1 EU/mg) as
analyzed with the Limulus amebocyte lysate (Pyrochrome)
method (Cape Cod Inc., Falmouth, MA, USA).
Antibody measurements
Enzyme immunoassays were performed as described ear-
lier [22]. Briefly, 96-well flat-bottom ELISA plates (Nunc
MaxiSorp; eBioscience, San Diego, CA, USA) were coated
with 10 μg/ml of recombinant COMP proteins, or with
10 μg/ml synthetic COMP peptide in PBS at 4°C and left
overnight. Plates were blocked with 1% bovine serum
albumin in PBS containing Tween, incubated with the
supernatants from hybridomas or sera, washed, and again
incubated with goat anti-mouse IgG peroxidase-conju-
gated antibodies (Jackson Immuno-Research, West Grove,
PA, USA) and ABTS tablets (Roche) as substrate. For iso-
type-specific assessment, biotinylated anti-IgM, -IgG1,
-IgG2a, -IgG2b, or -IgG3 reagents (Jackson Immuno-
Research, West Grove, PA, USA) were used for detection.
Passive transfer of antibodies and evaluation of arthritis
The anti-CII mAb (M2139) binding to the MPGERGAA-
GIAGPK epitope of the CB10 fragment (aa 551-564) of
the CII molecule used in this study was produced as
described earlier [6,19]. The cocktail of M2139 and
COMP mAbs and the combination of COMP mAbs were
prepared by mixing equal concentrations of each of the
sterile-filtered antibody solution to achieve a final amount
of 9 mg. On day 5 (or day 7), all the mice received 25 μg/
mouse lipopolysaccharide (LPS) from Escherichia coli ser-
otype O26:B6 (Sigma-Aldrich, Saint Louis, MO, USA)
intraperitoneally to enhance the severity of the arthritis
developed. Arthritis development was monitored daily in a
blinded fashion for 16 days using an extended scoring pro-
tocol [24]. Briefly, clinical arthritis is defined as swelling
and redness in the joint and was scored as follows: 1 point
was given for each swollen or red toe, 1 point for each
swollen joint (metatarsal phalangeal joints, metacarpal
phalangeal joints, proximal interphalangeal joints, and dis-
tal interphalangeal joints), and 5 points for a swollen ankle
(maximum score per limb was 15 and maximum score per
mouse was 60).
Histology
For histological assessments, knee joint and paws from
adult mice were dissected, decalcified, dehydrated, and
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then paraffin-embedded, as described previously [23].
Sections (5 μm) were stained with hematoxylin/eosin or
toluidine blue. For analysis of anti-COMP mAb reactiv-
ity with joint tissue in vivo, neonatal mice were injected
with 100 μg biotinylated mAbs against COMP intraperi-
toneally. After 24 h, knee joints were snap frozen in iso-
pentane on dry ice and stored at -70°C. Joint sections
(7 μm) were fixed in 4% paraformaldehyde for 5 minutes,
rinsed in PBS, incubated with Extravidin peroxidase
(Sigma-Aldrich, Saint Louis, MO, USA) for 30 minutes
and developed with diaminobenzidine (DAB Kit; Dako,
Copenhagen, Denmark) for 8 to 9 minutes. To assess
direct binding of anti-COMP mAbs to the tissue sections,
limbs from naïve neonatal mice were harvested and snap
frozen, cryo-sectioned, and sections of 7 μm were sub-
jected to 5 μg/ml biotinylated mAbs against COMP for
40 minutes. Extravidin peroxidase and DAB were used
for the detecting system.
Statistical analyses
Quantitative data are expressed as mean ± standard error
of the mean (SEM). Arthritis incidence was analyzed using
chi-square or Fisher’s exact test (SAS Institute; Cary, NC,
USA) and comparison of severity was performed using the
non-parametric Mann-Whitney U-test. Analysis of var-
iance (ANOVA) was used to analyze polyclonal Ab
response statistics. Differences with P-values less than 0.05
were considered statistically significant.
Results
Specificity of polyclonal antibodies to COMP
To perform epitope mapping of COMP, we expressed
recombinant his-tagged full-length mouse COMP and a
panel of overlapping COMP fragments in HEK 293-c18
cells (Figure 1A). All the recombinant proteins were puri-
fied using affinity and ion exchange chromatographic
methods. For each recombinant protein, the expected
apparent molecular weight and a purity of > 95% was veri-
fied by SDS-PAGE analysis (Figure 1B).
To ascertain whether antibodies show reactivity towards
individual full-length and truncated form of COMP pro-
teins, microtiter plates were coated with either recombi-
nant COMP molecules or COMP purified from rat
chondrosarcoma, and used in enzyme immunoassays with
sera obtained at 50 days after primary immunization. As
shown in Figure 1C, reaction with recombinant COMP
proteins was in the following order: pCOMP > mCOMP
approximately = EGF1-TIII8 approximately = EGF1-4 >
TIII1-CG > CG approximately = TIII1-8. Notably, of the
single domain fragments, reactivity to EGF1-4 is consider-
ably higher than to TIII1-8 or CG. However, in the native
fold, the TSP3 repeats (TIII1-8) are wrapped around the
C-terminal globule (CG) making direct comparison com-
plicated. Nevertheless, the lower reactivity to the TIII1-CG
fragment (the complete TSP3 and C-terminal globule frag-
ment), compared to all the fragments containing the EGF
repeats (pCOMP, mCOMP, EGF1-TIII8 and EGF1-4)
underlines an important role of the EGF repeats in the
immune response.
In COMP+/+Ncf1*/* mice, the incidence of arthritis was
80% with the day of disease onset at 36 to 38 days [17].
Since cross-reactions with autologous COMP appear to be
of importance for the development of arthritis, we analyzed
the antibody reactivity to the autologous mouse recombi-
nant full-length COMP and COMP fragments. Immunized
mice produced a rapid and strong IgG response as early as
14 days after immunization (Figure 1D). Antibody reactiv-
ity to both rat and mouse COMP showed a definite trend
of increasing serum titres, from day 14 onwards with a
peak response around day 50. Analysis of the kinetics of
antibody response to each of the recombinant COMP frag-
ments confirmed the important contribution of EGF
repeats to the overall immune response. Antibody levels to
the EGF1-4 fragment were higher than observed for TIII1-
8, CG and TIII1-CG fragments at all time points tested in
our experiments.
Generation and characterization of anti-COMP mAbs
To obtain a broad set of COMP-specific mAbs, we gener-
ated a panel of mAbs using COMP-deficient mice and
COMP-wild type mice with Ncf1 mutation immunized
with the native form of rat COMP during secondary
immune response. A total of 21 IgG mAbs from four sepa-
rate fusions were developed and sub-cloned to obtain
stable single clones. None of the COMP antibodies cross-
reacted to CII, which might be present as a minor con-
taminant with the rat COMP during protein preparation
from the Swarm rat chondrosarcoma. Isotype analysis
revealed that all of the COMP mAbs generated were of
IgG isotype, containing IgG1, IgG2a, and IgG2b subtypes,
indicating that they were indeed produced by T cell-
dependent follicular B cells (Table 1). Since we were inter-
ested in antibodies capable of inducing arthritis, we
screened each antibody for its ability to bind autologous
mouse COMP, a total of 18 mAbs reactive with rat
COMP cross-reacted with mouse COMP (Table 1). Five
of these 18 mAbs were cross-reactive to human COMP,
which suggests that these epitopes on the COMP molecule
are evolutionarily conserved.
For the detection of mAbs binding to different regions
of COMP molecule, we performed ELISA with the
recombinant COMP fragments. The binding properties
of 4 representative mAbs to the truncated COMP frag-
ments are shown in Figure 2. The 16B5 clone produced a
specific signal only with pCOMP, which is a full length
COMP molecule, but produced no signal with any of the
other COMP fragments. Hence, we deduced that 16B5
binding site is either located at the N-terminal coiled-coil
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pentamerization domain or a conformational discontinu-
ous epitope of pentameric COMP. The 15A11 clone
represents mAb with a binding site located at the EGF-
like repeat domain, which produced a specific signal with
pCOMP, mCOMP, EGF1-TIII8 and EGF1-4 fragments
but produced no signal with TIII1-8 and CG fragments.
This antibody does, however, also show reactivity to the
TIII1-CG fragment, although producing a lower signal.
The 1B8 clone represents mAb having a binding site
located at the TSP3 domain, which produced a specific
signal with pCOMP, mCOMP, EGF1-TIII8, TIII1-CG
and TIII1-8 fragments, but produced no signal with
EGF1-4 and CG fragments. The 1D10 clone represents
mAb binding to epitopes that are located at the C-term-
inal globular domain, which produced a strong specific
signal with the CG fragment, bound the CG containing
fragments pCOMP, mCOMP, TIII1-CG, but produced
little or no signal with the EGF1-4, EGF1-TIII8 and
TIII1-8 fragments. This mapping strategy using the
recombinant COMP fragments was applied on each of
the 18 mouse-specific mAbs. The mAbs binding sites
were thereby narrowed down to one of the COMP
domains. Among these 18 mAbs, 12 reacted with the
EGF-like domain. Alignment of the rat and mouse
COMP sequences revealed 15 amino acid differences
between the mature peptide sequences. Considering that
these differences could result in a strong immune
response, we produced 11 synthetic peptides correspond-
ing to the rat COMP sequence, each spanning one or
two variant residues. To fine map the anti-COMP mAb
epitopes, we performed ELISA on the 11 synthetic pep-
tides with the hope that some of the mAbs would react
to a linear peptide structure. As shown in Figure 3, the
peptide PSPCHEKADCILERDGSRS, which locates at
EGF-repeat 4, was found to bind the 15A11 mAb. None
of the other mAbs tested (16B5, 12H8, 1B8, 2D3, 3F8,
6H4) showed binding to any of the peptides tested.
Monoclonal antibodies specific for COMP bind cartilage
To test whether the mAbs bind with native COMP in
cartilage, COMP mAbs were biotinylated and injected
separately into neonatal COMP+/+ mice and the pre-
sence in joints of biotinylated mAbs after 24 h was ana-
lyzed using cryo-sections of whole paws. The mAbs
demonstrated specific binding to cartilage and synovial
tissue, with different affinity to the joint cartilage tissue
(Figure 4). The 1D10 and 15A11 mAbs gave detectable
staining, showing accumulation on the lining of the nor-
mal articular cavity, most visibly along the cartilage sur-
face and synovial tissue. In contrast, mAb 16B5 showed
no appreciable staining. The specificity for COMP was
verified by performing the same experiment in neonatal
COMP-/- mice, where no joint staining was observed
(Figure 4).
Table 1 Summary of mAb specificities
Clones Mice Isotypes Rat COMP Mouse COMP Human COMP Binding sites
1A12 COMP-/- IgG1 ++ ++ _ EGF-like domain
1B8 COMP-/- IgG1 + + _ TSP3 domain
1D10 COMP-/- IgG1 ++ ++ ++ C-terminal globular domain
2D3 COMP-/- IgG1 +++ +++ +++ coiled-coil domain or pentameric COMP
1C1 COMP-/- IgG2b + ++ _ EGF-like domain
3C7 COMP-/- IgG2b + _ _ ND
3F8 COMP-/- IgG2b ++ ++ _ EGF-like domain
4A8 COMP-/- IgG2b ++ ++ _ C-terminal globular domain
8E3 COMP-/- IgG1 ++ + _ EGF-like domain
12H8 COMP+/+ IgG1 +++ +++ _ EGF-like domain
15A11 COMP+/+ IgG1 +++ +++ +++ EGF-like domain
4D12 COMP-/- IgG2b + _ _ EGF-like domain
3F11 COMP-/- IgG2a ++ + _ EGF-like domain
16B5 COMP+/+ IgG1 +++ +++ +++ coiled-coil domain or pentamer COMP
18E7 COMP-/- IgG2b + + _ EGF-like domain
5E8 COMP-/- IgG2b + _ _ ND
6H4 COMP-/- IgG2b ++ ++ + EGF-like domain
29C3 COMP-/- IgG1 + +++ _ EGF-like domain
30G5 COMP-/- IgG2b ++ ++ _ C-terminal globular domain
23A8 COMP-/- IgG1 ++ +++ _ EGF-like domain
24F7 COMP-/- IgG2b ++ ++ _ EGF-like domain
Grading of values obtained with mAbs using culture supernatants. Scale for optical density (OD) values: -, < 3 times standard error of the mean (SEM) of negative
control; +, > 3 times SEM of negative control; ++, > 0.5 OD; +++, > 1.0 OD; COMP, cartilage oligomeric matrix protein; EGF, epithelial growth factor; ND, not
determined.
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Cartilage tissue is a dense ECM with a very high con-
centration of proteoglycans, suggesting that antibody
penetration into the tissue would be limited. In agree-
ment with this, the anti-collagen II (CII) mAb M2139
staining was restricted to the cartilage surface (Figure 4).
The 1D10 and 15A11 mAbs stainings, although weaker
than the CII staining, show the same pattern, with addi-
tional staining of the synovium and bone.
To verify the in vitro binding capacity of mAbs to car-
tilage, joint sections from untreated neonatal wild-type
or COMP-/- mice were incubated with the individual
biotinylated mAbs and binding of the antibody detected
by indirect immunohistochemistry (Figure 5). As
expected, mAb M2139 in this case gave uniform CII
staining throughout the cartilage from wild-type mice.
This was also the case for the three COMP mAbs that
showed clear cartilage staining in wild-type mice (1D10,
15A11 and 12H8).
COMP-specific monoclonal antibodies induce and
enhance severe acute arthritis in naïve mice
To investigate the pathogenic potential of COMP-specific
mAbs, (BALB/c × B10.Q) F1 mice were first injected with
single COMP-specific mAbs in combination with a sub-
arthritogenic dose of M2139, a CII specific IgG2b mAb.
This experimental design was chosen because most of the
COMP-specific mAbs are of the poorly complement-fixing
IgG1 isotype, and complement activation is one of the cri-
tical factors for development of arthritis [25,26]. We have
earlier reported that 4.5 mg of M2139 induced no visible
arthritis [7]. This dose was therefore chosen to use in
combination with different COMP-specific mAbs, to test
whether these mAbs could contribute to tissue injury by
enhancing the subclinical disease established by the CII-
specific M2139 antibody alone. Indeed, combination of
single COMP-specific mAbs with a sub-optimal dose of
M2139 mAb did induce arthritis (Figure 6A). Among the
Figure 2 Epitope mapping of 4 representative COMP-specific mAbs by using full-length cartilage oligomeric matrix protein (COMP)
and recombinant fragments. B cell hybridomas were produced from COMP+/+Ncf1*/* or COMP-/-Ncf1*/* immunized with rat COMP. Monoclonal
antibodies were obtained from culture supernatants after 14 days and tested by ELISA. Plates were individually coated with 10 μg/ml of
recombinant full-length mouse COMP or COMP fragments. Serum samples from naïve mice served as negative controls and serum samples from
COMP immunized mice were used as positive controls.
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different combinations tested, the 15A11 plus M2139, and
the 3F8 plus M2139 showed the most efficient arthrito-
genic activity. In the 15A11 plus M2139 group, all six
mice presented aggressive disease, which may indicate that
they were most effective at complementing each other. In
the 3F8 plus M2139 group, four out of six mice presented
aggressive disease (Figure 6A). To confirm the clinical
observations, paws from treated animals were subjected to
histopathological examination after the termination of the
experiments. In the tissue sections of arthritic mice, we
could detect inflammatory infiltration in the synovium
and articular cavity, synovial hyperplasia, pannus forma-
tion, bone and cartilage erosions, and furthermore proteo-
glycan loss was clearly evident (Figure 6B).
To further test whether a combination of antibodies to
the most dominant epitopes of COMP was arthritogenic,
anti-COMP mAbs 1B8, 1D10, 3F8, 15A11 and 16B5,
which bind sites located at different domains of COMP,
were mixed at equal concentrations and injected intrave-
nously into 2-month-old mice. Clinical symptoms of
arthritis developed in four out of six mice characterized by
a rapid onset albeit with a low disease severity (Figure 6C).
No signs of arthritis were observed in animals injected
with control monoclonal antibodies.
Discussion
COMP is expressed predominantly in cartilage and
synovium [11]. An immune response to COMP leads to
arthritis [16,17]. Here we clearly show that arthritogenic
antibodies are indeed produced after native COMP
immunization that are preferentially directed to the EGF
region of the COMP molecule, bind cartilage and induce
arthritis in naïve mice.
To analyze the epitope specificity of autoantibodies to
COMP, we injected mice with COMP and investigated the
ensuing polyclonal antibody response at different time
points. Furthermore, we generated monoclonal antibodies
from the responding B cells to characterize the fine speci-
ficity of various COMP antigenic determinants. Interest-
ingly, the polyclonal antibody response was dominated by
the reactivity to the EGF-like domain compared to the
TSP3 and C-terminal globular domains at all the time
points tested in our experiments. Similar to the anti-
COMP polyclonal response, the majority of the mAb (12
out of 18) binding sites are located on the EGF-like
domain. These results indicate that the EGF-like domain
is the highly immune-dominant region in the B cell
immune response to COMP. In the present study, we pro-
duced full-length mouse COMP, as well as a panel of over-
lapping COMP fragments in mammalian cells to preserve
the three-dimensional structure of the protein. These
recombinant COMP molecules allowed us to select mAbs
that are specifically binding to conformational COMP epi-
topes, which are highly dependent on the three-dimen-
sional structure. Although some investigators have
proposed that any surface patch of a protein can be an epi-
tope [27,28], in many cases, immunogenic hot spots are
focused on restricted parts of the corresponding autoanti-
gens in vivo [29,30]. In the present study, COMP B cell
immuno-dominant regions were found to be located at
the EGF-like domain of the COMP molecule.
Increase in synovial fluid and serum COMP level is used
as a bio-marker for cartilage turnover in human joint dis-
eases [31,32]. Several matrix metalloproteinase and
ADAMTS (a disintegrin and metalloprotease with throm-
bospondin motifs) family members such as ADAMTS-4,
-7 and -12 are responsible for COMP degradation [33-35].
Di Cesare and colleagues were able to resolve a major
reduction-sensitive 150 KD COMP fragment, which may
include the pentamerizing domain and some portion of
the type-2 repeats and non-reduction-sensitive 67 to 94
kDa fragments which must be C-terminal fragments pre-
sent in cartilage extracts of patients with RA and osteoar-
thritis (OA) [36]. The newly generated mAbs, specific in
the present study to COMP molecular domains, may
prove useful tools to detect such COMP degradation frag-
ments in the synovial fluid and serum. Hence, extensive
investigations are needed to test our mAbs for the detec-
tion of degradative fragments of COMP in the synovial
fluid and serum of arthritic patients.
Earlier, we reported that the affinity-purified COMP-spe-
cific polyclonal antibodies can induce arthritis in healthy
Figure 3 Fine mapping of selected cartilage oligomeric matrix
protein (COMP)-specific mAbs. To identify possible linear peptide
epitopes for anti-COMP mAbs, synthetic peptides from rat COMP
were produced. Each peptide spans amino acid residues differently in
the rat and mouse sequence. Antibodies were obtained from culture
supernatants after 14 days and tested by ELISA in wells individually
coated with 10 μg/ml of synthetic peptide. Pooled sera from COMP-
immunized mice were used as the positive control. Monoclonal Ab
15A11 bound peptide 6, which is derived from EGF repeat 4.
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Figure 4 Immunohistochemical analysis of cartilage oligomeric matrix protein (COMP)-specific mAbs binding to joint cartilage in vivo.
COMP specific-mAbs were purified, biotinylated and injected into neonatal COMP+/+ mice (100 μg of antibody in 100 μl of PBS/mice) and limbs
were collected after 24 h. Seven μm cryo-sections were stained with DAB using extravidin-peroxidase as the detection system. Anti-CII
monoclonal antibody (M2139)-injected animals served as positive controls, anti-COMP mAb injected COMP-/- mice were used as negative
controls. Positive mAb binding to joint surfaces is marked by arrows.
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Figure 5 Immunohistochemical analysis of cartilage oligomeric matrix protein (COMP)-specific mAbs binding to cartilage in vitro.
Immunohistochemistry was performed using 7 μm cryo-sections from naive neonatal mouse limbs, using 5 μg/ml of biotinylated COMP-specific
mAbs. Binding was detected by extravidin-peroxidase and DAB substrate. Sections from COMP+/+ mouse limbs stained with 12H8, 15A11, 1D10,
3F8, 1B8, 16B5 are depicted in the pictures. Sections from COMP-/- mouse limbs stained with 12H8, 15A11, 1D10, 3F8, 1B8, 16B5 were used as
negative controls. Anti-collagen type II (CII) monoclonal M2139 served as the positive control. The positive monoclonal staining on cartilage and
tendon is indicated with an arrow.
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Figure 6 Cartilage oligomeric matrix protein (COMP)-specific mAbs mediate arthritis. (A) Accumulated incidence and severity of arthritis.
Two-month-old naïve male QB F1 mice were injected intravenously (i.v.) with 9 mg of an equal combination of M2139 with a single COMP-
mAb. All the mice received lipopolysaccharide (25 μg per mouse) intraperitoneally on day 5 and were scored for arthritis up to 16 days. The
error bars in the severity graph indicate standard error of the mean (SEM), n = 6 per combination group. (B) Histology of tarsal joint sections.
Paws of QB F1 mice on day 16 after the antibody transfer were collected, fixed, decalcified, sectioned and stained with hematoxylin/eosin (left
panel) or toluidine blue (right panel). Top panel, M2139 plus PBS-injected control mice; Bottom panel, M2139 plus 15A11-injected mice. Note
thickened synovial lining, inflammatory cellular infiltrate extending over the cartilage surface and erosions of cartilage and bone in animals
injected with M2139 plus 15A11 (bottom). Results shown are representative of those obtained from three to four mice in each group. Infiltration
cells, glycosaminoglycan loss and joint surface erosions are indicated with arrows. (C) Accumulated incidence and severity of arthritis. Two-
month-old naïve male QB F1 mice were injected i.v. with 9 mg of an equal combination of 1B8, 1D10, 3F8, 15A11 and 16B5 anti-COMP
monoclonal antibodies (filled circles). The same amount of a combination of isotype-matched control antibodies (L243 + G11) was injected into
a separate group of animals (open circles). Results shown are pooled values from two similar experiments with balanced groups. The error bars
in (A) and (B) indicate the SEM.
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recipients [17]. Here, we generated, characterized and iden-
tified mAbs that can interact with the native conformation
of antigen present in the joint cartilage. Indeed, when wild-
type and COMP-/- mice, were immunized with COMP,
80% COMP+/+ mice developed severe arthritis, whereas
COMP-/- animals exhibited no clinical abnormalities (our
unpublished data). These differences in arthritis severity
are very likely a result of the absence of COMP as a target
for the anti-COMP immune response. In this study, we
provide evidence to show that mAbs to defined epitopes
on COMP are indeed pathogenic, thereby emphasizing a
link to COMP-mediated autoimmunity. Current observa-
tions of binding of COMP-specific mAbs directly to the
cartilage COMP in its native conformation, and the passive
transfer of COMP-specific mAbs leading to arthritis, have
important implications for the understanding of the ensu-
ing immune responses against COMP in arthritis. It has
been reported that antibodies play a pivotal role in trigger-
ing inflammation in arthritis [7,8,37]. It is most likely that
the first step in the initial triggering event in this transfer
model is the formation of COMP-IgG immune complexes
on the cartilage surface or in the synovium. Cartilage
COMP served as a target for the autoantibodies and these
immobilized immunoglobulins may activate the comple-
ment pathways and/or FcgR-bearing cells. Both C5a recep-
tor and FcgRIII have been reported to play co-dominant
roles in the CII antibody induced arthritis (CAIA) and glu-
cose-6-phosphate isomerase serum-induced arthritis
[38-40]. It has been reported that synovial macrophages
and neutrophils act downstream during the process of anti-
body-mediated joint inflammation [41,42].
In RA patients, joint-specific autoantigens are consid-
ered to play an important role in the induction of synovial
B cell expansion [43]. A sign of severe RA is the presence
of germinal center-like structures in the inflamed synovial
tissue, suggesting a locally generated B cell response to tis-
sue specific autoantigens [44]. Furthermore, a potential
role of COMP as an arthritogenic target in RA is derived
from clinical studies, where COMP fragments [45,46] and
antibody response to COMP [47] have been observed in
the serum samples and joint fluids. Recent studies also
showed that COMP has the potential to activate the alter-
native complement pathway and can inhibit the classical
and lectin pathways [48]. Thus, autoimmunity to COMP
could contribute to the pathogenesis of RA in maintaining
the active inflammatory processes ongoing in the inflam-
matory joint. In this respect, antibodies secreted by syno-
vial B cells could induce inflammatory joint damage in RA
patients, in similarity with animal experiments.
Conclusions
We elucidated specificities of autoantibodies to COMP
and its contribution to the development of arthritis. These
findings will further improve our understanding of the
autoantibody-mediated immunopathologies occurring
widely in RA as well as in other autoimmune disorders.
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